{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:28:00Z","timestamp":1787120880851,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Talquetamab, a first-in-class G protein\u2013coupled receptor family C group 5 member D (GPRC5D) \u00d7 CD3 bispecific antibody, demonstrates substantial clinical activity in relapsed\/refractory multiple myeloma (RRMM). However, immune dysfunction associated with advanced disease, extensive prior therapies, and bispecific antibody\u2013mediated immune modulation may increase susceptibility to infections. This systematic review and meta-analysis aimed to characterize infection risk associated with talquetamab, with separate evaluation of monotherapy and combination therapy settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, Web of Science Core Collection, and Cochrane Library databases were searched from inception to July 1, 2026. Studies reporting infection outcomes among RRMM patients treated with talquetamab-containing regimens were eligible. Outcomes included any-grade infections, grade \u22653 infections, infection-related mortality, reported pathogens, and preventive strategies when available. Because talquetamab monotherapy and combination regimens represent clinically distinct treatment strategies, quantitative analyses were restricted to monotherapy cohorts, whereas combination therapy studies were summarized descriptively. A random-effects model was used to estimate pooled infection incidence. Methodological quality was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six studies were included in the qualitative synthesis, including four talquetamab monotherapy cohorts and two talquetamab-based combination therapy cohorts. Quantitative meta-analysis included four monotherapy cohorts comprising 735 patients for any-grade infections and three cohorts comprising 584 patients for grade \u22653 infections. The pooled incidence of any-grade infections was 51% (95% CI, 34%\u201367%; I\u00b2 = 94.2%), while the pooled incidence of grade \u22653 infections was 22% (95% CI, 17%\u201328%; I\u00b2 = 59.6%). Given the limited number of available studies and substantial heterogeneity, these pooled estimates should be interpreted as exploratory and hypothesis-generating. Combination therapy cohorts, including talquetamab plus teclistamab and talquetamab-based regimens from MonumenTAL-3, demonstrated substantial infection burdens and were characterized descriptively rather than quantitatively. Infection-related mortality ranged from 0% to 3.2%. Frequently reported infections included viral infections (particularly SARS-CoV-2 and cytomegalovirus), bacterial pneumonia, and opportunistic infections such as Pneumocystis jirovecii pneumonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Talquetamab monotherapy in heavily pretreated RRMM patients is associated with a clinically meaningful risk of infections, including severe infections. The substantial heterogeneity observed across studies likely reflects differences in patient characteristics, prior therapies, treatment settings, infection definitions, and supportive care strategies. Combination bispecific antibody regimens may represent a potentially higher infection burden requiring enhanced infection surveillance and preventive approaches. Further prospective studies are warranted to better define infection risk factors and optimal prevention and management strategies during talquetamab therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD420261357352<\/jats:ext-link>\n                      , identifier CRD420261357352.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1848518","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:48:23Z","timestamp":1787118503000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Infection risk associated with talquetamab in relapsed\/refractory multiple myeloma: a systematic review with meta-analysis of talquetamab monotherapy and descriptive analysis of combination therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Zeng-Yi","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Hematology, Gaozhou People\u2019s Hospital","place":["Maoming, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gaozhou People\u2019s Hospital","place":["Maoming, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoyu","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gaozhou People\u2019s Hospital","place":["Maoming, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital, Jinan University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Lian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gaozhou People\u2019s Hospital","place":["Maoming, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12185-024-03766-4","article-title":"Bispecific antibodies for multiple myeloma: past, present and future","volume":"120","author":"Ochi","year":"2024","journal-title":"Int J Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01945-x","article-title":"Talquetamab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/nejmoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14353","article-title":"Talquetamab in multiple myeloma: efficacy, safety, and future directions","volume":"114","author":"Labanca","year":"2025","journal-title":"Eur J Haematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41408-025-01386-7","article-title":"Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"15","author":"Al Hadidi","year":"2025","journal-title":"Blood Cancer J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70114","article-title":"A German multicenter real-world analysis of talquetamab in 138 patients with relapsed\/refractory multiple myeloma","volume":"9","author":"Frenking","year":"2025","journal-title":"Hemasphere"},{"key":"B13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-025-01254-4","article-title":"Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients","volume":"15","author":"Chunara","year":"2025","journal-title":"Blood Cancer J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016490","article-title":"Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels","volume":"9","author":"Banerjee","year":"2025","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1565407","article-title":"Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.31222\/osf.io\/v7gm2_v1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews","volume":"1","author":"Booth","year":"2012","journal-title":"Syst Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.11124\/jbisrir-d-19-00099","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.32614\/cran.package.meta","article-title":"meta: An R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R News"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70376","article-title":"Real-world evaluation of talquetamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group Immunotherapy Registry real-world analysis","volume":"101","author":"Janakiram","year":"2026","journal-title":"Am J Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2604657","article-title":"Talquetamab-daratumumab in relapsed or refractory myeloma","author":"Mina","year":"2026","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016613","article-title":"Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1","volume":"9","author":"Schinke","year":"2025","journal-title":"Blood Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.3390\/cancers17172727","article-title":"Safety and efficacy of bispecific antibody treatment in relapsed\/refractory multiple myeloma: a systematic review and meta-analysis of proportions from clinical trials","volume":"17","author":"Bakogeorgou","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157858","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1848518\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:48:24Z","timestamp":1787118504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1848518\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2026.1848518"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1848518","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1848518"}}